For family members and guardians
A plain-language summary of the cited sources below. Informational only — not medical advice.
Risperidone is a medication that affects certain chemical messengers in the brain, particularly dopamine and serotonin. Doctors prescribe it to help manage serious mental health conditions such as schizophrenia and bipolar disorder, and sometimes to reduce severe behavioural disturbances when other approaches haven't worked. In the disability context, it's occasionally used when someone experiences very challenging behaviours that cause harm to themselves or others, though this is not its primary purpose. The medication stays active in the body for around 24 hours, which is why it's usually taken once daily.
Like all antipsychotic medications, risperidone can cause side effects. The most common include feeling drowsy or restless, headaches, and increased levels of a hormone called prolactin, which can affect periods, breast tissue, or sexual function. Some people experience akathisia — an uncomfortable urge to keep moving that can be distressing. More serious but rare side effects include involuntary muscle movements that may become permanent (tardive dyskinesia), a dangerous reaction called neuroleptic malignant syndrome involving high fever and muscle rigidity, and severe allergic reactions. If your family member develops a high fever, muscle stiffness, confusion, or uncontrollable movements, seek medical help immediately.
Because risperidone affects brain chemistry and can sedate or calm behaviour, Behaviour Support Practitioners are required to assess whether it's being used primarily to manage behaviour rather than treat a diagnosed mental health condition. This review isn't about whether the medication is "bad" — it's about ensuring your family member has the right supports in place, that the medication is genuinely benefiting them, and that less restrictive approaches have been properly considered alongside it.
For prescribers
A plain-language summary of the cited sources below. Informational only — not medical advice.
Risperidone is a second-generation antipsychotic with high affinity for both serotonergic 5-HT₂ and dopaminergic D₂ receptors. It is indicated for schizophrenia, acute mania, bipolar I disorder, and behavioural disturbances in adults. The parent compound has a short half-life of approximately three hours, but its active metabolite 9-hydroxy-risperidone extends pharmacological activity to around 24 hours, providing once-daily dosing utility. Risperidone is metabolised via CYP2D6; clinicians should consider potential interactions with CYP2D6 inhibitors (which may elevate risperidone levels in extensive metabolisers) and note that poor metabolisers will have higher parent-drug exposure. Common adverse effects include hyperprolactinaemia (reported in up to 11.7% of patients), akathisia, sedation, and headache. Serious risks encompass neuroleptic malignant syndrome, tardive dyskinesia, and rare haematological and dermatological reactions. Elevated prolactin warrants monitoring, particularly in longer-term use.
When risperidone is prescribed for behavioural purposes—such as aggression, agitation, or self-injury—in an NDIS participant, it falls within the Restrictive Practices framework as a regulated chemical restraint. The BSP contacting you is seeking documentation that confirms the clinical indication, the specific behaviour(s) the prescription addresses, and that ongoing monitoring (metabolic parameters, movement disorders, prolactin where clinically indicated) is in place. This is not a challenge to prescribing autonomy but a statutory requirement under the NDIS Quality and Safeguards Commission's rules: any psychotropic used to manage behaviour must be reported, have a behaviour-support plan in place, and demonstrate regular clinical review. If your prescription is for a diagnosed psychiatric condition (schizophrenia, bipolar disorder) rather than behavioural management, clarifying that distinction in correspondence will assist the BSP in meeting their compliance obligations without imposing unnecessary oversight on standard psychiatric care.
Mechanism & pharmacology
“Risperidone is a selective monoaminergic antagonist with a high affinity for serotoninergic 5- HT2 and dopaminergic D2 receptors.”
“After oral administration to psychotic patients, risperidone is eliminated with a half-life of about 3 hours. The elimination half-life of 9-hydroxy- risperidone and of the active moiety is 24 hours.”
“Risperidone is metabolised by CYP2D6 to 9-hydroxy-risperidone, which has a similar pharmacological activity as risperidone.”
TGA-approved indications
- RISVAN is indicated for the treatment of schizophrenia in adults for whom tolerability and effectiveness has been established with oral risperidone.↗TGA PIT1✓
PBS-subsidised indications
- Behavioural disturbances↗PBST2✓
Show clinical criteria
Behavioural disturbances Clinical criteria: Treatment Phase: Initial treatment Clinical criteria: The condition must be characterised by psychotic symptoms and aggression, AND Patient must have dementia of the Alzheimer type, AND Patient must have failed to respond to non-pharmacological methods of treatment, AND Patient must not receive more than 12 weeks of treatment under this restriction. A patient may only qualify for 12 weeks of PBS-subsidised treatment under this restriction once in a 12 month period. Note: No increase in the maximum quantity or number of units may be authorised.
- Schizophrenia↗PBST2✓
Show clinical criteria
Schizophrenia Clinical criteria: For a patient switching from oral risperidone, the prescriber must determine the patient dosage of this drug based on the current dose of oral risperidone according to the dose transition table in the Therapeutic Goods Administration (TGA) approved Product Information. Note: For the purpose of administering this restriction, Schizophrenia refers to schizophrenia spectrum disorders outlined in the DSM-5 criteria.
- Acute mania↗PBST2✓
Show clinical criteria
Acute mania Clinical criteria: Clinical criteria: The condition must be associated with bipolar I disorder, AND The treatment must be as adjunctive therapy to mood stabilisers, AND The treatment must be limited to up to 6 months per episode. Note: For the purpose of administering this restriction, Schizophrenia refers to schizophrenia spectrum disorders outlined in the DSM-5 criteria.
- Bipolar I disorder↗PBST2✓
Show clinical criteria
Bipolar I disorder Clinical criteria: Clinical criteria: The condition must be refractory to treatment, AND The treatment must be in combination with lithium or sodium valproate, AND The treatment must be maintenance therapy. Note: For the purpose of administering this restriction, Schizophrenia refers to schizophrenia spectrum disorders outlined in the DSM-5 criteria.
- Severe behavioural disturbances↗PBST2✓
Show clinical criteria
Severe behavioural disturbances Clinical criteria: Clinical criteria: Patient must have autism spectrum disorder, AND The treatment must be under the supervision of a paediatrician or psychiatrist, AND The treatment must be in combination with non-pharmacological measures. Population criteria: Patient must be under 18 years of age. Behaviour disturbances are defined as severe aggression and injuries to self or others where non-pharmacological methods alone have been unsuccessful. The diagnosis of autism spectrum disorder must be made based on the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V) or ICD-10 international classification of mental and behavioural disorders.
Adverse effects
Common (top 5)
- blood prolactin increased (11.7%)↗TGA PIT1✓
- hyperprolactinaemia (7.2%)↗TGA PIT1✓
- akathisia (5.5%)↗TGA PIT1✓
- headache (4.8%)↗TGA PIT1✓
- somnolence (4.1%)↗TGA PIT1✓
Serious
- neuroleptic malignant syndrome↗TGA PIT1✓
- tardive dyskinesia↗TGA PIT1✓
- agranulocytosis↗TGA PIT1✓
- anaphylactic reaction↗TGA PIT1✓
- Stevens- Johnson syndrome and toxic epidermal necrolysis↗TGA PIT1✓
Curated subset. The full adverse-effect list is in the TGA Product Information; click any citation above to open it.
Contraindications
- Hypersensitivity to the active substance or to any of the excipients listed in Section 6.1 List of excipients.↗TGA PIT1✓
Regulated practice context
A plain-language summary of the cited sources below. Informational only — not medical advice.
- Regulator framework: Risperidone prescribed to influence behaviour falls under the NDIS Quality and Safeguards Commission's regulated restrictive practices framework as chemical restraint. Implementing providers must hold state/territory authorisation, engage a specialist behaviour support provider, lodge the resulting behaviour support plan with the Commission, and submit monthly reports on the practice's use.↗NDIS CommissionT2✓
- Risperidone is one of the most frequently encountered medications in BSP review. When prescribed for behavioural disturbance rather than a primary psychotic illness, confirm the prescribed indication matches the documented purpose. A divergence between the stated indication (e.g. "schizophrenia") and the observed function (e.g. PRN administration triggered by behavioural escalation) is a recognised pattern for chemical-restraint review under the NDIS framework.↗NDIS RulesT2✓
- Statutory anchor: the regulated-restrictive-practices framework applied to Risperidone when prescribed as chemical restraint sits under the National Disability Insurance Scheme Act 2013, the parent statute under which the NDIS (Restrictive Practices and Behaviour Support) Rules 2018 are made and the NDIS Quality and Safeguards Commission operates.↗NDIS ActT2✓
- Commonwealth clinical-quality overlay: Risperidone use in people with cognitive disability or impairment is governed by the ACSQHC Psychotropic Medicines in Cognitive Disability or Impairment Clinical Care Standard (2024). The Standard's eight quality statements require thorough assessment, non-medication strategies tried first, individualised behaviour planning, clear treatment goals, and regular review with deprescribing where appropriate — applying across all settings where the person receives care.↗ACSQHC Psychotropic Medicines Clinical Care StandardT2✓
Jurisdictional framework
Showing Commonwealth (national). Other states remain visible below.
Other jurisdictions (15)
- ACT: In the Australian Capital Territory, use of Risperidone as chemical restraint is regulated by the Senior Practitioner Act 2018 (ACT), which establishes the Office of the Senior Practitioner with independent oversight across disability services, education, residential care, and child protection. A Positive Behaviour Support Plan must justify the practice as the least-restrictive option, with active reduction strategies. The ACT framework's stated aim is the reduction and elimination of restrictive practices.
- QLD: In Queensland, use of Risperidone as chemical restraint by funded disability service providers is governed by the Disability Services Act 2006 (Qld) and the positive behaviour support / restrictive practices framework administered by the Department of Families, Seniors, Disability Services and Child Safety. Authorisation must follow assessment by an appropriately qualified practitioner, a Positive Behaviour Support Plan, and the legislative tests of least-restrictive practice and reduction planning. Authorisation is granted per restrictive-practice type — separate authorisation is required for each.
- SA: In South Australia, use of Risperidone as chemical restraint is a Level 2 restrictive practice under the SA Restrictive Practices Authorisation Scheme (in force from 30 May 2022) and can only be authorised by the Senior Authorising Officer — Authorised Program Officers cannot approve chemical restraint. Authorisation requires a Behaviour Support Plan, advice from a Specialist Behaviour Support Practitioner, and consultation with the participant and their family. The scheme is administered by the Restrictive Practices Unit within the Department of Human Services.
- WA: In Western Australia, use of Risperidone as chemical restraint requires authorisation through a Quality Assurance Panel under the WA Department of Communities Authorisation of Restrictive Practices framework (effective 1 December 2020). The panel must include at least two decision-makers: a senior manager from the implementing provider and an independent NDIS Behaviour Support Practitioner external to that provider who did not write the Behaviour Support Plan. Unlike single-administrator state models, the panel decision is the authorisation.
- NSW: In New South Wales, use of Risperidone as chemical restraint by a registered NDIS provider must be authorised under the NSW Restrictive Practices Authorisation framework administered by the Department of Communities and Justice (DCJ). Authorisation requires a Behaviour Support Plan documenting the practice, evidence that it is the least-restrictive option, and a documented reduction strategy. Psychotropic medications used as restraint should be reviewed at least every six months by a medical practitioner and at least every twelve months by a psychiatrist.
- TAS: In Tasmania, use of Risperidone as chemical restraint by a disability service provider requires authorisation by the Tasmanian Senior Practitioner under the Disability Rights, Inclusion and Safeguarding Act 2024 (Tas). The Senior Practitioner authorises, oversees, and reports on restrictive practice use in NDIS-funded and Department of Communities Services–funded disability services, with a statutory requirement to protect the rights of people subject to restrictive practices to the greatest extent possible.
- NT: In the Northern Territory, use of Risperidone as chemical restraint by a registered NDIS service provider requires authorisation by the NT Senior Practitioner via the Restrictive Practice Authorisation System administered by NT Health. Applications must include the Behaviour Support Plan, evidence of consultation with the participant and relevant others, particulars of the providers applying the practice, and a summary of every restrictive practice applied in the preceding 12 months.
- QLD: In Queensland, use of Risperidone as chemical restraint on an adult with disability requires consent from a restrictive-practices guardian appointed by the Queensland Civil and Administrative Tribunal (QCAT), or short-term approval by the chief executive of the relevant disability service while a Positive Behaviour Support Plan is being developed. The Office of the Public Guardian acts as substitute decision-maker where appointed. Use must be the least-restrictive option to prevent serious harm and is subject to reduction planning.
- VIC: In Victoria, use of Risperidone as chemical restraint requires authorisation by the Victorian Senior Practitioner under the Disability Act 2006 (Vic). Authorisation must satisfy the legislative tests of necessity to prevent harm, least-restrictive option, and a documented reduction plan.
- VIC: Statutory anchor: Risperidone use as chemical restraint in Victoria is regulated by the Disability Act 2006 (Vic), Part 7 of which establishes the Senior Practitioner role and the regulated-restrictive-practice authorisation framework. The Act's tests of necessity, least-restrictive option, and reduction planning are statutorily binding.
- TAS: Statutory anchor: Risperidone use as chemical restraint by disability service providers in Tasmania is regulated by the Disability Rights, Inclusion and Safeguarding Act 2024 (Tas), which establishes the Tasmanian Senior Practitioner with statutory powers to authorise, oversee, and report on restrictive-practice use in NDIS-funded and Department of Communities Services–funded disability services.
- ACT: Statutory anchor: Risperidone use as chemical restraint in the ACT is regulated by the Senior Practitioner Act 2018 (ACT). The Act's stated object is the reduction and elimination of restrictive practices and it applies broader-than-NDIS oversight: disability services, education, residential care, and child protection all sit within scope.
- QLD: Statutory anchor: substitute decision-making for Risperidone use as chemical restraint on adults with impaired capacity in Queensland is governed by the Guardianship and Administration Act 2000 (Qld). Chapter 5B Part 4 sets out QCAT's powers to appoint a restrictive-practices guardian and the Office of the Public Guardian's role as substitute decision-maker.
- QLD: Statutory anchor: Risperidone use as chemical restraint by funded disability service providers in Queensland is regulated by the Disability Services Act 2006 (Qld), Chapter 5B of which sets out the positive behaviour support and restrictive-practice authorisation framework. The PBSRP Reform Bill 2024 lapsed in October 2024; the existing framework remains in force.
- SA: Statutory anchor: Risperidone use as chemical restraint in South Australia is regulated by the Disability Inclusion Act 2018 (SA), with the operative detail in the Disability Inclusion (Restrictive Practices — NDIS) Regulations 2021. Together they establish the two-tier authorisation scheme (Authorised Program Officer for Level 1, Senior Authorising Officer for Level 2 including chemical restraint) in force from 30 May 2022.
The reasoning structure on this page is largely transferable to the parallel aged-care restrictive-practices framework administered by the Aged Care Quality and Safety Commission. The Commonwealth statute (Aged Care Act 1997) governs in place of the NDIS Rules; the medication-context analysis is otherwise the same.